Hereditary angioedema (HAE) is characterized by unpredictable episodic swelling without pruritus. Attacks can be severe, sometimes life-threatening, causing significant morbidity and disability.1,2
Patients with HAE are subject to localized attacks of subcutaneous and/or submucosal swelling. Typical therapies for angioedema are ineffective in patients with HAE; thus, a correct diagnosis is crucial.
Depending on the severity of the disease, some patients will have frequent attacks, while others may have a few throughout the year.12 Many people have their first attack in childhood; attacks typically worsen after puberty and persist through adulthood.2
Physical exertion, stress and trauma are among the most commonly reported triggers of an attack.3
Gösswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Bork K, Oldenburg J, Müller CR. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res. 2008;121(3-4):181-8. doi: 10.1159/000138883. Epub 2008 Aug 28
Patients with HAE Types 1 and 2 have a mutation on the SERPING1 gene, causing a deficiency or dysfunction in the plasma protein C1 inhibitor (C1-INH).4 For 75% of patients, the mutation is autosomal dominant and heterozygous for the deficiency;13 for the other 25%, the mutation is spontaneous.2
HAE Type 1 is a quantitative and functional deficiency of C1-INH. Type 1 is the most common, with 85% of people having this type.2
HAE Type 2 is a function deficiency, whereby the body makes normal to high amounts of C1-INH, but it does not work properly. 15% of people have Type 2.
There is a third type of HAE for which patients have both normal levels and normal functioning C1-INH. This website addresses HAE Types 1 and 2 only.
HAE accounts for approximately 2% of clinical angioedema cases. It affects 1 in ~67,000, so there are roughly 6,000 people in the U.S. living with the disease;6 attacks lead to 15,000–30,000 ED visits per year.7 The average HAE patient has 26 attacks per year (~2 attacks per month); however, there are rare reports of patients with more than 100 HAE attacks per year.12
Because the condition is so rare, and often misdiagnosed, exact numbers are difficult to calculate.
There are no apparent differences in prevalence based on sex or ethnicity.8
C1‐INH is a broad-spectrum serine proteinase inhibitor, named for its ability to inhibit C1—the first component of the complement cascade. It also inhibits other circulating enzymes such as kallikrein and activated coagulation factor XII (FXIIa).
Produced primarily in the liver, C1-INH is a major regulator of the complement, fibrinolytic, contact, and coagulation cascades. In HAE, the deficiency or dysfunction in C1-INH causes these cascades to continue unchecked. The end result is an overproduction of bradykinin, a type of nonapeptide. By binding to the B2 receptor on vascular endothelial cells, bradykinin causes vascular permeability, leading to edema, ascites, and hypotension.
Source: MacGinnitie, Andrew J. 2013. “Pediatric hereditary angioedema.” Pediatric Allergy and Immunology 25 (5): 420-427. doi:10.1111/ pai.12168. http://dx.doi.org/10.1111/pai.12168.
 Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458-67.
 Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013;19(7 Suppl):s103-110.
 Zotter Z, Csuka D, Szabó E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44.
 Gösswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res. 2008;121(3-4):181-188.
 Kado RK, Carlson J, Wild LG. Can HAE be Identified and Diagnosed Earlier if a Complement 4 Level is Done on All Patients Presenting with Acute Angioedema. J Allergy Clin Immunol. 2011;127(2):AB47.
 Frank MH. Hereditary angioedema. Medscape. August 30, 2018. https://emedicine.medscape.com/article/135604-overview.
 Cicardi M, Zuraw BL. Angioedema Due to Bradykinin Dysregulation. J Allergy Clin Immunol Pract. 2018;6(4):1132-1141.
 Gelincik A and Demir S. Hereditary Angioedema. May 31, 2017. DOI: 10.5772/intechopen.68208
 2010 Lumry – The humanistic burden of HAE impact on HRQOL, productivity, and depressionREFERENCEvf1.15
 Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;48(4):256-227.
 Maurer et al. World Allergy Organization Journal (2018) 11:5 DOI 10.1186/s40413-017-0180-1 Page 6, Table 5 (p.7)
Are You a Healthcare Professional?
The information in this section is intended for US healthcare professionals only.